{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:29:42Z","timestamp":1787020182381,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T00:00:00Z","timestamp":1628553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T00:00:00Z","timestamp":1628553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To analyze the long-term effects of persistent subretinal fluid (SRF) on visual\/anatomic outcomes according to the type of macular neovascularization (MNV) during relaxed treat-and-extend regimen with anti-vascular endothelial growth factor (anti-VEGF) agents in age-related macular degeneration (AMD) patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with fovea-involving type 1 or type 2 MNV, treated with a relaxed treat-and-extend regimen for 2\u2009years were retrospectively reviewed. Eyes with SRF observed more than three times per year were defined as the \u2018persistent SRF (+) group\u2019. To exclude the effects of IRF as much as possible, the eyes with persistent IRF were excluded. The effects of persistent SRF on the best-corrected visual acuity (BCVA), central subfield retinal thickness (CST), and changes in the photoreceptor layer (PRL) thickness and outer retinal bands (external limiting membrane, ellipsoid zone, and cone outer segment tip line) after anti-VEGF injection were analyzed for each MNV type.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seventy-seven eyes with type 1 MNV (44 eyes with persistent SRF) and 53 eyes with type 2 MNV (18 eyes with persistent SRF) were enrolled. Following a relaxed treat-and-extend regimen with anti-VEGF agents, BCVA and CST improved for each MNV type. In comparison between persistent SRF (+) and persistent SRF (\u2212) group, there were no differences in the amount of change in BCVA and CST between the two groups for each MNV type during 2-year follow-up periods. In addition, there were no differences in the amount of reduction in PRL thickness and state of the outer retinal bands between the two groups for each MNV type.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Using a relaxed treat-and-extend regimen with anti-VEGF agents, persistent SRF did not have additional effects on visual and anatomic outcomes by 2\u2009years, regardless of the MNV type.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12886-021-02063-6","type":"journal-article","created":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T18:02:39Z","timestamp":1628618559000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Analyses of the effects of persistent subretinal fluid on visual\/anatomic outcomes according to the type of macular neovascularization during the relaxed treat-and-extend protocol in age-related macular degeneration patients"],"prefix":"10.1186","volume":"21","author":[{"given":"Kyung Tae","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju Byung","family":"Chae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seungheon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eoi Jong","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Yoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,10]]},"reference":[{"issue":"1","key":"2063_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.preteyeres.2007.07.005","volume":"27","author":"W Drexler","year":"2008","unstructured":"Drexler W, Fujimoto JG. State-of-the-art retinal optical coherence tomography. Prog Retin Eye Res. 2008;27(1):45\u201388. https:\/\/doi.org\/10.1016\/j.preteyeres.2007.07.005.","journal-title":"Prog Retin Eye Res"},{"issue":"20","key":"2063_CR2","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","volume":"364","author":"DF Martin","year":"2011","unstructured":"Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897\u2013908. https:\/\/doi.org\/10.1056\/NEJMoa1102673.","journal-title":"N Engl J Med"},{"issue":"7","key":"2063_CR3","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1097\/IAE.0000000000000902","volume":"36","author":"SS Wickremasinghe","year":"2016","unstructured":"Wickremasinghe SS, Janakan V, Sandhu SS, Amirul-Islam FM, Abedi F, Guymer RH. Implication of recurrent or retained fluid on optical coherence tomography for visual acuity during active treatment of neovascular age-related macular degeneration with a treat and extend protocol. Retina. 2016;36(7):1331\u20139.","journal-title":"Retina"},{"issue":"4","key":"2063_CR4","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.ophtha.2010.12.019","volume":"118","author":"FG Holz","year":"2011","unstructured":"Holz FG, Amoaku W, Donate J, Guymer RH, Kellner U, Schlingemann RO, et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology. 2011;118(4):663\u201371. https:\/\/doi.org\/10.1016\/j.ophtha.2010.12.019.","journal-title":"Ophthalmology."},{"issue":"1","key":"2063_CR5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ajo.2009.01.024","volume":"148","author":"GA Lalwani","year":"2009","unstructured":"Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol. 2009;148(1):43\u201358.e1.","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"2063_CR6","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","volume":"121","author":"U Schmidt-Erfurth","year":"2014","unstructured":"Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V, Nguyen QD, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014;121(1):193\u2013201. https:\/\/doi.org\/10.1016\/j.ophtha.2013.08.011.","journal-title":"Ophthalmology."},{"issue":"9","key":"2063_CR7","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1016\/j.ophtha.2016.05.016","volume":"123","author":"GJ Jaffe","year":"2016","unstructured":"Jaffe GJ, Kaiser PK, Thompson D, Gibson A, Saroj N, Vitti R, et al. Differential response to anti-VEGF regimens in age-related macular degeneration patients with early persistent retinal fluid. Ophthalmology. 2016;123(9):1856\u201364. https:\/\/doi.org\/10.1016\/j.ophtha.2016.05.016.","journal-title":"Ophthalmology."},{"issue":"7","key":"2063_CR8","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","volume":"119","author":"DF Martin","year":"2012","unstructured":"Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388\u201398. https:\/\/doi.org\/10.1016\/j.ophtha.2012.03.053.","journal-title":"Ophthalmology."},{"issue":"4","key":"2063_CR9","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.ophtha.2014.11.017","volume":"122","author":"U Schmidt-Erfurth","year":"2015","unstructured":"Schmidt-Erfurth U, Waldstein SM, Deak GG, Kundi M, Simader C. Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration. Ophthalmology. 2015;122(4):822\u201332. https:\/\/doi.org\/10.1016\/j.ophtha.2014.11.017.","journal-title":"Ophthalmology."},{"issue":"4","key":"2063_CR10","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.ajo.2015.06.025","volume":"160","author":"A Dirani","year":"2015","unstructured":"Dirani A, Ambresin A, Marchionno L, Decugis D, Mantel I. Factors influencing the treatment response of pigment epithelium detachment in age-related macular degeneration. Am J Ophthalmol. 2015;160(4):732\u20138.e2.","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"2063_CR11","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1097\/IAE.0000000000000505","volume":"35","author":"T Sato","year":"2015","unstructured":"Sato T, Suzuki M, Ooto S, Spaide RF. Multimodal imaging findings and multimodal vision testing in neovascular age-related macular degeneration. Retina. 2015;35(7):1292\u2013302.","journal-title":"Retina"},{"issue":"5","key":"2063_CR12","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.ophtha.2018.11.025","volume":"126","author":"RH Guymer","year":"2019","unstructured":"Guymer RH, Markey CM, McAllister IL, Gillies MC, Hunyor AP, Arnold JJ. Tolerating subretinal fluid in Neovascular age-related macular degeneration treated with Ranibizumab using a treat-and-extend regimen: fluid study 24-month results. Ophthalmology. 2019;126(5):723\u201334. https:\/\/doi.org\/10.1016\/j.ophtha.2018.11.025.","journal-title":"Ophthalmology."},{"issue":"5","key":"2063_CR13","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s00417-010-1588-2","volume":"249","author":"R H\u00f6rster","year":"2011","unstructured":"H\u00f6rster R, Ristau T, Sadda SR, Liakopoulos S. Individual recurrence intervals after anti-VEGF therapy for age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2011;249(5):645\u201352. https:\/\/doi.org\/10.1007\/s00417-010-1588-2.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"2063_CR14","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ophtha.2012.07.042","volume":"120","author":"GS Ying","year":"2013","unstructured":"Ying GS, Huang J, Maguire MG, Jaffe GJ, Grunwald JE, Toth C, et al. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology. 2013;120(1):122\u20139. https:\/\/doi.org\/10.1016\/j.ophtha.2012.07.042.","journal-title":"Ophthalmology."},{"key":"2063_CR15","doi-asserted-by":"publisher","unstructured":"Kim KT, Lee H, Kim JY, Lee S, Chae JB, Kim DY. Long-term visual\/anatomic outcome in patients with fovea-involving fibrovascular pigment epithelium detachment presenting choroidal neovascularization on optical coherence tomography angiography. J Clin Med. 2020;9(6):1863. https:\/\/doi.org\/10.3390\/jcm9061863.","DOI":"10.3390\/jcm9061863"},{"issue":"9","key":"2063_CR16","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1097\/IAE.0b013e3181e7976b","volume":"30","author":"KB Freund","year":"2010","unstructured":"Freund KB, Zweifel SA, Engelbert M. Do we need a new classification for choroidal neovascularization in age-related macular degeneration? Retina. 2010;30(9):1333\u201349.","journal-title":"Retina"},{"issue":"4","key":"2063_CR17","doi-asserted-by":"publisher","first-page":"e0216304","DOI":"10.1371\/journal.pone.0216304","volume":"14","author":"Y Nakano","year":"2019","unstructured":"Nakano Y, Kataoka K, Takeuchi J, Fujita A, Kaneko H, Shimizu H, et al. Vascular maturity of type 1 and type 2 choroidal neovascularization evaluated by optical coherence tomography angiography. PLoS One. 2019;14(4):e0216304. https:\/\/doi.org\/10.1371\/journal.pone.0216304.","journal-title":"PLoS One"},{"issue":"1","key":"2063_CR18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12886-016-0207-3","volume":"16","author":"JJ Arnold","year":"2016","unstructured":"Arnold JJ, Markey CM, Kurstjens NP, Guymer RH. The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration--a phase IV randomised clinical trial with ranibizumab: the FLUID study. BMC Ophthalmol. 2016;16(1):31. https:\/\/doi.org\/10.1186\/s12886-016-0207-3.","journal-title":"BMC Ophthalmol"},{"key":"2063_CR19","doi-asserted-by":"publisher","unstructured":"Kim KT, Lee H, Kim JY, Chae JB, Hyung S, Kim DY. Association between early anatomic response and intraocular pressure change after intravitreal dexamethasone implant: an optical coherence tomography study. J Clin Med. 2020;9(9):2692. https:\/\/doi.org\/10.3390\/jcm9092692.","DOI":"10.3390\/jcm9092692"},{"issue":"3","key":"2063_CR20","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.ophtha.2008.10.006","volume":"116","author":"SG Schuman","year":"2009","unstructured":"Schuman SG, Koreishi AF, Farsiu S, Jung SH, Izatt JA, Toth CA. Photoreceptor layer thinning over drusen in eyes with age-related macular degeneration imaged in vivo with spectral-domain optical coherence tomography. Ophthalmology. 2009;116(3):488\u201396.e2.","journal-title":"Ophthalmology"},{"key":"2063_CR21","doi-asserted-by":"publisher","first-page":"361513","DOI":"10.1155\/2013\/361513","volume":"2013","author":"D Odrobina","year":"2013","unstructured":"Odrobina D, Lauda\u0144ska-Olszewska I, Gozdek P, Maroszy\u0144ski M, Amon M. Morphologic changes in the foveal photoreceptor layer before and after laser treatment in acute and chronic central serous chorioretinopathy documented in spectral-domain optical coherence tomography. J Ophthalmol. 2013;2013:361513.","journal-title":"J Ophthalmol"},{"issue":"9","key":"2063_CR22","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1097\/IAE.0000000000000188","volume":"34","author":"R Hoerster","year":"2014","unstructured":"Hoerster R, Muether PS, Sitnilska V, Kirchhof B, Fauser S. Fibrovascular pigment epithelial detachment is a risk factor for long-term visual decay in neovascular age-related macular degeneretion. Retina. 2014;34(9):1767\u201373.","journal-title":"Retina"},{"issue":"3","key":"2063_CR23","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1167\/iovs.09-5018","volume":"52","author":"I Golbaz","year":"2011","unstructured":"Golbaz I, Ahlers C, Stock G, Sch\u00fctze C, Schriefl S, Schlanitz F, et al. Quantification of the therapeutic response of intraretinal, subretinal, and subpigment epithelial compartments in exudative AMD during anti-VEGF therapy. Invest Ophthalmol Vis Sci. 2011;52(3):1599\u2013605. https:\/\/doi.org\/10.1167\/iovs.09-5018.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"10","key":"2063_CR24","doi-asserted-by":"publisher","first-page":"6448","DOI":"10.1167\/iovs.11-9162","volume":"53","author":"F Sulzbacher","year":"2012","unstructured":"Sulzbacher F, Kiss C, Kaider A, Eisenkoelbl S, Munk M, Roberts P, et al. Correlation of SD-OCT features and retinal sensitivity in neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2012;53(10):6448\u201355. https:\/\/doi.org\/10.1167\/iovs.11-9162.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"9","key":"2063_CR25","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1016\/j.ophtha.2013.01.073","volume":"120","author":"GJ Jaffe","year":"2013","unstructured":"Jaffe GJ, Martin DF, Toth CA, Daniel E, Maguire MG, Ying GS, et al. Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2013;120(9):1860\u201370. https:\/\/doi.org\/10.1016\/j.ophtha.2013.01.073.","journal-title":"Ophthalmology."},{"key":"2063_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.preteyeres.2015.07.007","volume":"50","author":"U Schmidt-Erfurth","year":"2016","unstructured":"Schmidt-Erfurth U, Waldstein SM. A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration. Prog Retin Eye Res. 2016;50:1\u201324. https:\/\/doi.org\/10.1016\/j.preteyeres.2015.07.007.","journal-title":"Prog Retin Eye Res"},{"issue":"12","key":"2063_CR27","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1136\/bjophthalmol-2014-305186","volume":"98","author":"M Ritter","year":"2014","unstructured":"Ritter M, Simader C, Bolz M, De\u00e1k GG, Mayr-Sponer U, Sayegh R, et al. Intraretinal cysts are the most relevant prognostic biomarker in neovascular age-related macular degeneration independent of the therapeutic strategy. Br J Ophthalmol. 2014;98(12):1629\u201335. https:\/\/doi.org\/10.1136\/bjophthalmol-2014-305186.","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"2063_CR28","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/j.ophtha.2013.12.029","volume":"121","author":"C Simader","year":"2014","unstructured":"Simader C, Ritter M, Bolz M, De\u00e1k GG, Mayr-Sponer U, Golbaz I, et al. Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration. Ophthalmology. 2014;121(6):1237\u201345. https:\/\/doi.org\/10.1016\/j.ophtha.2013.12.029.","journal-title":"Ophthalmology."},{"issue":"2","key":"2063_CR29","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1136\/bjo.2008.143974","volume":"94","author":"M Bolz","year":"2010","unstructured":"Bolz M, Simader C, Ritter M, Ahlers C, Benesch T, Pr\u00fcnte C, et al. Morphological and functional analysis of the loading regimen with intravitreal ranibizumab in neovascular age-related macular degeneration. Br J Ophthalmol. 2010;94(2):185\u20139. https:\/\/doi.org\/10.1136\/bjo.2008.143974.","journal-title":"Br J Ophthalmol"},{"issue":"12","key":"2063_CR30","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537\u201348. https:\/\/doi.org\/10.1016\/j.ophtha.2012.09.006.","journal-title":"Ophthalmology."},{"issue":"9900","key":"2063_CR31","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/S0140-6736(13)61501-9","volume":"382","author":"U Chakravarthy","year":"2013","unstructured":"Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013;382(9900):1258\u201367. https:\/\/doi.org\/10.1016\/S0140-6736(13)61501-9.","journal-title":"Lancet."},{"issue":"4","key":"2063_CR32","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.ajo.2007.02.024","volume":"143","author":"R Spaide","year":"2007","unstructured":"Spaide R. Ranibizumab according to need: a treatment for age-related macular degeneration. Am J Ophthalmol. 2007;143(4):679\u201380. https:\/\/doi.org\/10.1016\/j.ajo.2007.02.024.","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"2063_CR33","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ophtha.2015.09.018","volume":"123","author":"K Berg","year":"2016","unstructured":"Berg K, Hadzalic E, Gjertsen I, Forsaa V, Berger LH, Kinge B, et al. Ranibizumab or bevacizumab for Neovascular age-related macular degeneration according to the Lucentis compared to Avastin study treat-and-extend protocol: two-year results. Ophthalmology. 2016;123(1):51\u20139. https:\/\/doi.org\/10.1016\/j.ophtha.2015.09.018.","journal-title":"Ophthalmology."},{"issue":"1","key":"2063_CR34","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/IAE.0000000000001496","volume":"38","author":"D Barthelmes","year":"2018","unstructured":"Barthelmes D, Nguyen V, Daien V, Campain A, Walton R, Guymer R, et al. Two year outcomes of \u201ctreat and extend\u201d intravitreal therapy using aflibercept preferentially for neovascular age-related macular degeneration. Retina. 2018;38(1):20\u20138.","journal-title":"Retina"},{"issue":"1","key":"2063_CR35","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ophtha.2017.07.014","volume":"125","author":"R Silva","year":"2018","unstructured":"Silva R, Berta A, Larsen M, Macfadden W, Feller C, Mon\u00e9s J. Treat-and-extend versus monthly regimen in neovascular age-related macular degeneration: results with Ranibizumab from the trend study. Ophthalmology. 2018;125(1):57\u201365. https:\/\/doi.org\/10.1016\/j.ophtha.2017.07.014.","journal-title":"Ophthalmology."}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-021-02063-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-021-02063-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-021-02063-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T18:02:41Z","timestamp":1628618561000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-021-02063-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,10]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2063"],"URL":"https:\/\/doi.org\/10.1186\/s12886-021-02063-6","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,10]]},"assertion":[{"value":"29 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the Ethics Committee of Chungbuk National University Hospital (No. 2020\u201312-018). The institutional review board and ethics committees of Chungbuk National University Hospital (No. 2020\u201312-018) waived the need for informed consent. The study adhered to the tenets of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflicts interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"294"}}